Trends and outcome of statin therapy in dialysis patients with atherosclerotic cardiovascular diseases: A population-based cohort study
Authors:
Open Access
- 2 June 2023
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (6) , e0286670
Abstract
Background: Although statins are an effective strategy for the secondary prevention of atherosclerotic cardiovascular disease (ASCVD) in the general population, the benefits for dialysis patients are controversial. We sought to assess trends of statin use and evaluate outcomes of statin therapy in dialysis patients with different types of ASCVD. Methods: This nationwide retrospective population-based cohort study using data from the Korean National Health Insurance Service included adult patients (aged ≥ 18 years) undergoing chronic dialysis who had an initial ASCVD event in the time period of 2013 to 2018. Annual trends of statin use according to age, sex, and ASCVD types were analyzed. The association between 1-year mortality and statin use was examined using multivariable Cox proportional hazards regression analyses. Results: Among 17,242 subjects, 9,611(55.7%) patients were statin users. The overall prevalence of statin use increased from 52.9% in 2013 to 57.7% in 2018; the majority (77%) of dialysis patients were prescribed moderate-intensity statins. The proportions of low- or moderate-intensity statin use were similar, but high-intensity statin use increased from 5.7% in 2013 to 10.5% in 2018. The use of the statin/ezetimibe combination has gradually increased since 2016. Statin use was independently associated with the reduced 1-year all-cause mortality after adjusting for confounding factors (hazard ratio [HR] 0.89, 95% confidence interval [CI] 0.80–0.96, P = 0.004). Conclusion: The prevalence of statin prescriptions in dialysis patients after ASCVD event increased from 2013 to 2018. Most patients received moderate-intensity statin. However, high-intensity statin and statin/ezetimibe combination therapy has remarkably increased. Statin use was associated with decreased 1-year all-cause mortality in dialysis patients with ASCVD.Keywords
Funding Information
- Research Foundation of Internal Medicine, The Catholic University of Korea
This publication has 32 references indexed in Scilit:
- Lipid-Lowering Therapy in Persons With Chronic Kidney DiseaseAnnals of Internal Medicine, 2012
- Rosuvastatin in Diabetic Hemodialysis PatientsJournal of the American Society of Nephrology, 2011
- Atorvastatin and Low-Density Lipoprotein Cholesterol in Type 2 Diabetes Mellitus Patients on HemodialysisClinical Journal of the American Society of Nephrology, 2011
- The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trialThe Lancet, 2011
- Rosuvastatin and Cardiovascular Events in Patients Undergoing HemodialysisNew England Journal of Medicine, 2009
- Intensive Lipid Lowering With Atorvastatin in Patients With Coronary Heart Disease and Chronic Kidney DiseaseJACC, 2008
- Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trialsBMJ, 2008
- Atorvastatin in Patients with Type 2 Diabetes Mellitus Undergoing HemodialysisNew England Journal of Medicine, 2005
- Beneficial Cardiovascular Pleiotropic Effects of StatinsCirculation, 2004
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987